Compare AbCellera Biologics Inc (ABCL) vs Snowflake Inc (SNOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Snowflake Inc — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while Snowflake Inc trades at $258.74 (market cap $91.07B). The key difference: Snowflake Inc is far larger — about 38.8× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | SNOW | |
|---|---|---|
Market Cap | $2.35B | $91.07B |
Sector | Health | Technology |
52-Week High | $8.12 | $280.16 |
52-Week Low | $2.78 | $121.11 |
Enterprise Value | $1.99B | $90.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SNOW trades at $262.74, up 1.0% today, with a bullish technical outlook from moving averages and strong analyst consensus. The stock shows accelerating revenue growth, reaching $3.63B in 2025, but remains unprofitable with a net income margin of -23.79%. Recent news highlights AI Data Cloud traction and partnerships driving optimism, while cash flow from operations improved to $959.76M.
Outlook is positive due to AI-driven growth and consistent earnings beats, but high valuation (P/S 17.74) and persistent losses pose risks. Wall Street's $294.31 price target suggests ~12% upside, though competition and execution challenges require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
